<?xml encoding="utf-8" ?> Health Canada has given the go-ahead to Lipocine Inc. LPCN and its licensing partner, Verity ...

Health Canada approved TLANDO for testosterone replacement therapy in adult men with hypogonadism, with Lipocine’s commercial ...

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through Lipocine's licensing partner Verity ...

Shares of Lipocine (LPCN) surged more than 30% in pre-market trading on Wednesday after Health Canada approved its oral testosterone replacement therapy, expanding its commercial footprint into a ...

If approved, KYZATREX could become the only oral testosterone option available in Canada. KYZATREX received U.S. FDA approval in July 2022. “We are excited by this first international filing and look ...

TLANDO is approved by Health Canada as a testosterone replacement therapy in adult males indicated for conditions associated with a deficiency or absence of endogenous testosterone (male hypogonadism) ...

RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company focused on developing innovative therapies for Testosterone Deficiency, is pleased to ...

Following the news, Lipocine shares rose more than 25% to $2.64. TLANDO is an oral formulation of testosterone undecanoate available as 112.5 mg capsules. In January 2024, Lipocine and Verity Pharma ...